767-70-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzothiazole, 7-bromo(7CI,8CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs with improved therapeutic effects.
Used in Agrochemical Production:
Benzothiazole, 7-bromo(7CI,8CI) is also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals that protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
Benzothiazole, 7-bromo(7CI,8CI) serves as an important intermediate in organic synthesis, enabling the creation of a wide range of organic compounds with diverse applications in various industries.
Used in Fluorescent Dyes and Optical Brighteners:
Benzothiazole, 7-bromo(7CI,8CI) is employed in the preparation of fluorescent dyes and optical brighteners, which are used in various applications such as imaging, sensing, and improving the appearance of fabrics and other materials.
Used as a Corrosion Inhibitor:
Benzothiazole, 7-bromo(7CI,8CI) is utilized as a corrosion inhibitor, protecting metals and alloys from degradation and extending their service life in various industrial applications.
Used in Antiviral Applications:
Due to its potential antiviral properties, Benzothiazole, 7-bromo(7CI,8CI) is of interest in medicinal chemistry for the development of antiviral agents that can combat viral infections and diseases.
Used in Anticancer Applications:
Benzothiazole, 7-bromo(7CI,8CI) is being explored for its potential anticancer properties, with the aim of developing new therapeutic agents that can target and inhibit the growth of cancer cells.
Used in Antimicrobial Applications:
Benzothiazole, 7-bromo(7CI,8CI) is also considered for its antimicrobial properties, making it a promising candidate for the development of new antimicrobial agents to combat bacterial and fungal infections.

InChI:InChI=1/C7H4BrNS/c8-5-2-1-3-6-7(5)10-4-9-6/h1-4H

Upstream product

• 1123-55-3 7-amino-1,3-benzothiazole 
• 769-20-0 6-amino-7-bromo-1,3-benzothiazole 
• 533-30-2 1,3-benzothiazol-6-amine 

Downstream Products

• 1326714-48-0 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole 
• 882055-21-2 2-Bromo-7-(4-fluoro-phenyl)-benzothiazole 
• 882055-20-1 7-(4-Fluoro-phenyl)-2-thiophen-3-yl-benzothiazole 
• 882055-27-8 4-[7-(4-Fluoro-phenyl)-benzothiazol-2-yl]-thiophene-2-sulfonic acid 
• 882055-39-2 4-[7-(4-Fluoro-phenyl)-benzothiazol-2-yl]-thiophene-2-sulfonyl chloride 
• 20358-05-8 7-bromo-1,3-benzothiazol-2-amine 
• 96426-78-7 benzothiazole-7-thiol 
• 882055-19-8 7-(4-fluoro-phenyl)-benzothiazole 

Relevant academic research and scientific papers

Method for synthesizing benzothiazole by microwave radiation of benzothioamide compound in aqueous phase

The invention discloses a method for synthesizing benzothiazole by microwave radiation of a benzothioamide compound in an aqueous phase. The method includes the steps: adding the benzothioamide compound into the aqueous phase under microwave conditions; performing cyclization under alkaline conditions to generate the benzothiazole. The method for preparing the benzothiazole is environmentally friendly, simple and convenient in operation, safe, cheap and efficient. Compared with the prior art, the method is applicable to a lot of functional groups, high in yield, few in by-products, simple in operation, safe, low in cost and environmentally friendly.

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)- thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors

4-(1,3-Benzothiazol-2-yl)thiophene-2-sulfonamide (4a) was found to be a moderately potent inhibitor of cyclin-dependent kinase 5 (cdk5) from a HTS screen. The synthesis and SAR around this hit is described. The X-ray coordinates of ligand 4a with cdk5 are also reported, showing an unusual binding mode to the hinge region via a water molecule.

New Compounds Useful for Treating CNS Disorders

The present invention provides new compounds of formula (I) as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.